Fig. 2: Maternal anti-S IgG activity across SARS-CoV-2 vaccine platforms in patients with and without positive history of infection. | Nature Communications

Fig. 2: Maternal anti-S IgG activity across SARS-CoV-2 vaccine platforms in patients with and without positive history of infection.

From: SARS-CoV-2 vaccination, booster, and infection in pregnant population enhances passive immunity in neonates

Fig. 2

a Comparing maternal anti-S IgG response between vaccine platforms mRNA1273 (Moderna, purple) and BNT162b2 (Pfizer-BioNTech, orange) in patients without a history of infection stratified by vaccination status at time of delivery; Partially vaccinated without a history of infection (PartVx), Fully vaccinated without a history of infection (FullVx), Boosted without a history of infection (BoostVx). b Comparing maternal anti-S IgG response between vaccine platforms mRNA1273 (Moderna, purple) and BNT162b2 (Pfizer-BioNTech, orange) in patients with a positive history of infection stratified by vaccination status at time of delivery; Partially vaccinated with a positive history of infection (PartVx/Inf), Fully vaccinated with a positive history of infection (FullVx/Inf) and Boosted with a positive history of infection (BoostVx/Inf). For a, b, data points are indicated as dots and plotted as boxplots (center line, median; bounds of box, the first and third quartiles; whiskers, 1.5 times interquartile range). Significance was determined by two-sided Wilcoxon rank-sum Test. Source data are provided as a source data file.

Back to article page